ArticleFrontiers in public health2026
Drug resistance characteristics and risk factors in patients with retreated pulmonary tuberculosis: a 5-year retrospective study in Suzhou, China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We conducted a systematic evaluation of TB-infected patient data from January 2020 to December 2024 to statistically analyze retreatment risk factors and drug resistance profiles among culture-positive TB patients in Suzhou. Methods: This investigation assessed the incidence of TB retreatment and drug resistance patterns in Suzhou, Jiangsu Province, China. Patients were stratified by diagnosis year, sex, age, and disease status. Using individual case records of pulmonary TB patients, drug resistance screening results, and clinical data of drug-resistant patients (01/01/2020-31/12/2024), we employed the chi-square test for group comparisons and multivariate logistic regression to identify influencing factors. Results: From 2020-2024, a total of 10,898 TB patients were enrolled, including 6,820 Conclusion: Bronchiectasis, anemia, fatty liver, hepatitis B, and extensively drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.